For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Chubb Limited (CB) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -2 (−100…+100 Quality+Value blend) · Quality 76 · Value -65 · Sentiment 9 (timing only, not weighted) · Composite fair value $300.09 vs $352.54 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Chubb Limited
CB NYSEChubb Limited is a global insurance and reinsurance company that provides commercial and personal property and casualty coverage, personal accident and health insurance, reinsurance, and life insurance. Chubb Limited serves businesses, individuals, and institutions through a broad range of products that include property, liability, workers’ compensation, specialty, and high-value personal lines, as well as risk management, claims, and loss-control services. Its operations are organized across North America commercial and personal insurance, North America agricultural insurance, overseas general insurance, global reinsurance, and corporate activities. The company also offers protection and savings solutions such as term life, dental, critical illness, and annuity products. Headquartered in Zurich, Switzerland, Chubb Limited plays a significant role in the international insurance market by supporting risk transfer and financial protection across multiple sectors and geographies.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 25.68
Total Equity: $79.78B
Shares: 401,499,998
Total Debt: $17.23B
Cash: $2.47B
EBITDA: N/A
Total Debt: $17.23B
Cash: $2.47B
Revenue: $59.78B
Revenue: $59.78B
Revenue: $59.78B
Total Equity: $79.78B
Tax Rate: 18.6%
Equity: $79.78B
Total Debt: $17.23B
Cash: $2.47B
Current Liabilities: N/A
Long-Term Debt: $15.73B
Total Debt: $17.23B
Total Equity: $79.78B
Shares: 401,499,998
Shares: 401,499,998
CapEx: $0.00
Shares: 401,499,998
Stock Price: $348.30
Net Income: $10.31B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 5, 2026 9:36am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $40.9B | $43.1B | $49.8B | $56.2B | $59.8B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $3.2B | $3.4B | $4.1B | $4.4B | $4.6B |
| Operating Income | — | — | — | — | — |
| Net Income | $8.5B | $5.2B | $9.0B | $9.3B | $10.3B |
| EBITDA | — | — | — | — | — |
| EPS | $20.02 | $12.81 | $21.94 | $22.70 | $25.68 |
| EPS (Diluted) | $19.27 | $12.55 | $21.80 | $22.51 | $25.68 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:36am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.8B | $2.1B | $2.6B | $2.5B | $2.5B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $200.1B | $199.1B | $230.7B | $246.5B | $272.3B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $15.2B | $14.4B | $13.0B | $14.4B | $15.7B |
| Total Liabilities | $140.3B | $148.6B | $167.0B | $178.2B | $192.5B |
| Total Equity | $59.7B | $50.5B | $63.7B | $68.4B | $79.8B |
| Retained Earnings | $47.4B | $48.3B | $54.8B | $61.6B | $70.0B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 4:53am (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $11.1B | $11.2B | $12.6B | $16.2B | $12.8B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | $0 | -$5.0B | -$34.0M | -$538.0M | -$289.0M |
| Net Debt Issued / (Repaid) | $1.6B | -$1.0B | -$475.0M | $971.0M | $1.6B |
| Dividends Paid | -$1.4B | -$1.4B | -$1.4B | -$1.4B | -$1.5B |
| Stock Buybacks | -$4.9B | -$2.9B | -$2.4B | -$1.8B | -$3.7B |
| Net Change in Cash | -$25.0M | $316.0M | $494.0M | -$72.0M | -$79.0M |
Growth Trends (YoY %)
Last updated: Aug 5, 2026 9:36am (18d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +5.4% | +15.7% | +12.7% | +6.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -38.5% | +72.1% | +2.7% | +11.2% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:36am (18d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-12 | $1.02 | — | — | — |
| 2026-03-13 | $0.97 | — | — | — |
| 2025-06-13 | $0.97 | — | — | — |
| 2025-03-14 | $0.91 | — | — | — |
| 2024-12-13 | $0.91 | — | — | — |
| 2024-09-13 | $0.91 | — | — | — |
| 2024-06-14 | $0.91 | — | — | — |
| 2024-03-14 | $0.86 | — | — | — |
| 2023-12-14 | $0.86 | — | — | — |
| 2023-09-14 | $0.86 | — | — | — |
| 2023-06-15 | $0.86 | — | — | — |
| 2023-03-16 | $0.83 | — | — | — |
| 2022-12-15 | $0.83 | — | — | — |
| 2022-09-15 | $0.83 | — | — | — |
| 2022-06-16 | $0.83 | — | — | — |
| 2022-03-17 | $0.80 | — | — | — |
| 2021-12-16 | $0.80 | — | — | — |
| 2021-09-16 | $0.80 | — | — | — |
| 2021-06-17 | $0.80 | — | — | — |
| 2021-03-18 | $0.78 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:40| Case | Growth | Margin | Fair value | vs price ($352.54) |
|---|---|---|---|---|
| Bull — recovery | +15% | 21.2% | $628.69 | +78% |
| Base — stabilizes | +10% | 18.5% | $471.16 | +34% |
| Bear — keeps slipping | +5% | 15.7% | $345.47 | -2% |
| Stress — last quarter repeats | +6% | 18.5% | $415.62 | +18% |
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw quarterlies first: Chubb ran rev of $13.35B/$14.84B/$16.15B/$15.07B/$14.77B across Q1'25 through Q1'26 — that's not a clean growth story, that's noisy with a Q3'25 spike (likely catastrophe-related premium/investment income timing) and a soft Q1'26 print. TTM revenue is roughly $60.8B vs FY24 $56.15B, so ~8% growth, decelerating from the 9.5% five-year CAGR. Net income TTM is ~$11.3B, up from $10.31B in FY25 — genuine earnings momentum, and the 11.2% recent earnings YoY beats the 6.9% earnings CAGR. Margins are the tell: Q1'26 at 15.7% versus Q4'25 at 21.3% and Q2'25 at 20% — the margin band is 10-21% over five quarters, which is exactly what you'd expect from a P&C book with cat losses and investment mark timing. ROE 12.9%, ROA 3.79%, D/E 0.22 — clean balance sheet, $79.8B equity, $17.2B debt. P/B 1.76x on 12.9% ROE implies the market pays ~14x normalized earnings for a mid-teens-ROE insurer, which is exactly fair for the archetype.
Now the model disagreement. The Valuation Synthesis says fair value $280 (-21% downside), Market Forces calls it a "leveraged bond fund" with a 10x FCF/earnings divergence, and the Narrative layer says 26% premium is justified by hard-market durability. These are contradictory but the synthesis and market-forces both understate what P&C accounting does to FCF — insurance FCF is dominated by reserve/float mechanics and is not comparable to industrial FCF. Calling Chubb a "leveraged bond fund" is technically true of every insurer and adds no information; the question is whether the underwriting combined ratio is disciplined, and Chubb's has been sub-90 for years. So I'd weight Market Forces low. The DCF-implied $280 assumes normalized underwriting margins and reversion; the actual issue is that at $348 and 13.6x P/E, the market isn't pricing heroic growth — it's pricing continued 12-13% ROE, which Chubb is delivering. A DCF that spits out $280 is probably using a discount rate that ignores insurance float economics.
The contrarian case: insider activity leans distinctly to selling — five S-Sale entries in three months of 2026, including a 20,176-share sale on 5/27 and 8,502 on 7/28, with only small A-Awards offsetting. Insiders don't sell into strength if they think reserves are conservative and the hard market has legs. Second, revenue confidence is flagged decelerating, and Q1'26 at $14.77B is below Q3'25's $16.15B and below Q1'25's implied run-rate ex-cat. Third, the FY25 → FY24 → FY23 earnings walk ($10.31B → $9.27B → $9.03B) shows earnings growth of only 3% between 2023 and 2024 — the 6.9% earnings CAGR is being carried by 2021's $8.53B base and the recent hard-cycle bump. If pricing softens in 2026-27 (which reinsurance signals already suggest at Jan 1 renewals), the earnings line flattens and the multiple compresses toward 11-12x. Fourth, climate/litigation tail risk is real — one bad hurricane season or a California wildfire subrogation reversal and you get a $2B EPS event.
GPT Reading
Chubb looks like exactly what the market thinks it is: a very high-quality P&C insurer, but at $348 it is being paid for as though the current earnings quality and pricing environment are unusually durable. The raw numbers are strong. Revenue has gone from $40.9B in 2021 to $59.8B in 2025, a 46% increase in four years, while net income rose from $8.5B to $10.3B despite the ugly 2022 reset to $5.3B. That tells me the franchise has real earnings resilience through insurance cycles rather than straight-line growth. Quarterly results also show decent momentum: 2026 Q1 revenue of $14.77B was up about 10.6% from $13.35B a year earlier, and net income of $2.32B was up roughly 75% from a weak prior-year quarter. But the sequence matters: after peaking at $16.15B in 2025 Q3, revenue stepped down to $15.07B and then $14.77B, and net margin swung from 21.3% in 2025 Q4 to 15.7% in 2026 Q1. That is not alarming for an insurer, but it does not support paying a premium as if earnings are compounding smoothly.
The valuation is where I part ways with any casually bullish read. At 13.6x earnings and 1.76x book, Chubb is not optically expensive versus the broad market, but for a mature insurer those are full multiples, especially with reported ROE only 12.9% and a dividend yield just 1.1%. Put differently, the market is valuing $79.8B of equity at $134.4B for a business that earned $10.3B last year. That is a solid return profile, not a spectacular one. A 12.9% ROE business trading at 1.76x book implies investors are underwriting sustained superior underwriting discipline, benign reserve development, and continued favorable pricing. Maybe Chubb deserves some premium for execution, but not an unlimited one. If earnings normalize closer to the 2024-2025 range of $9.3B-$10.3B and book compounds at a low-teens rate, I get to a fairer range around 1.4x-1.6x book, or roughly $280-$320 depending on interim book growth. That is below today’s price.
I also don’t buy the more dramatic bearish framing that this is “a leveraged bond fund masquerading as an insurer,” at least not from the data here. Operating cash flow was $12.8B in 2025 against $10.3B of net income, which is healthy, and debt is only $17.2B versus $79.8B of equity, a debt-to-equity ratio of 0.22. This is not balance-sheet stress. The business is earning real money and converting it into cash. The concern is subtler: a great insurer can still be a mediocre stock when bought too rich. Revenue CAGR of 9.5% since 2021 is good, but earnings CAGR of 6.9% is merely decent and reflects cycle noise. The stock’s current valuation asks you to believe Chubb can keep posting near-17% net margins on nearly $60B of revenue while also preserving premium rating quality. That is possible, but the upside from that starting point is limited.
The best counterargument is straightforward and serious. Chubb has earned the premium. Net income has exceeded $9B in three straight years after the 2022 hit, recent year-over-year Q1 earnings rebounded sharply, the balance sheet is conservative, and the payout ratio is only 14.6%, leaving ample room for buybacks, dividends, and capital flexibility. In insurance, consistency deserves a higher multiple because downside survival matters more than upside optionality. If you compare Chubb not to an average insurer but to a best-in-class allocator with underwriting discipline, then 1.76x book is not crazy. The insider tape is also not especially useful as a negative signal here; what we see is mostly routine sales, awards, gifts, and option exercises rather than heavy conviction selling. I weigh all of that positively. I just think the market already does too.
What would change my mind is evidence that the earnings base is stepping up rather than oscillating around a cycle peak. If the next few quarters show revenue holding above $15B while net income stays comfortably above $2.7B per quarter, implying an annual run rate north of $11B without margin erosion, then today’s multiple becomes much easier to defend and even modestly attractive. Alternatively, if book value is compounding fast enough that the current price falls toward 1.5x book without a stock correction, the valuation concern fades. On the other side, if margins stay in the mid-teens and revenue keeps slipping from the 2025 Q3 high, the stock should not be trading near $350.
Grok Reading
Chubb’s numbers describe a high-quality P&C franchise still compounding through a favorable pricing cycle rather than a stretched growth story. Revenue scaled from $40.9B in 2021 to $59.8B in 2025, a 9.5% CAGR, with 2025 net income of $10.31B delivering a 17.3% net margin and roughly $12.8B of operating cash flow against only $17.2B of debt and a 0.22 debt-to-equity ratio. Quarterly run-rate has held in a $14–16B band with margins oscillating between 10% and 21% as cat and reserve noise comes through; the soft Q1 2025 print (10% margin, $1.33B NI) was followed by three much stronger quarters and a solid Q1 2026 at 15.7%. At $348 and 13.6x trailing earnings, 1.76x book, and a 13% ROE, the market is paying a modest quality premium—not a heroic multiple—for mid-teens returns on equity, low leverage, and a sub-15% payout that leaves ample capital for float growth and buybacks. The 11% recent earnings y/y and durable underwriting franchise are what stand out; this is cash-generative maturity, not a bond fund in disguise.
The valuation engine’s $280 fair-value anchor (implying ~21% downside from current levels) collides with the lived fundamentals. A 13.6x P/E on a business that just produced $10.3B of net income and $12.8B of operating cash, with revenue still growing mid-single to high-single digits and ROE near 13%, is not expensive relative to historical Chubb ranges or to the scarcity of clean global underwriting platforms. The “alarming” 0.7% FCF CAGR is the weakest quantitative signal, but for a P&C carrier free-cash-flow definitions are noisy around reserve development and investment-portfolio accounting; operating cash conversion above net income is the cleaner tell. Insider activity is routine option-related selling and gifts, not a directional flag. Macro headwinds and a decelerating quarterly revenue trend are real but already visible in a single-digit forward growth assumption that a 13–14x multiple can absorb.
The strongest case against this read is straightforward: the composite DCF and signal-adjusted work says $279–281, the hard market will eventually soften, climate and social-inflation tails are underpriced, and you are paying a 26% premium to modeled normalized value for a cyclical mature earner whose earnings CAGR (6.9%) already lags revenue. If the pricing cycle rolls over and combined ratios drift back toward 95–97 while investment yields compress, the 13% ROE and 17% net margin both mean-revert and a 13.6x multiple becomes 11x in a hurry. That is the coherent bear arithmetic, and it is why the engine flags vulnerability to disappointment. I weigh it less heavily because Chubb’s underwriting track record, geographic mix, and capital discipline have historically protected margins better than the average carrier through soft patches, and because 1.76x book with a fortress balance sheet and 1.1% yield already embeds a non-trivial discount rate for those risks.
I would flip to outright overvalued if trailing or forward P/E pushed through 16–17x without an acceleration in earned premium or ROE, if the next two catastrophe seasons produced combined ratios sustainably above 95, or if full-year 2026 revenue growth fell below 3% with flat-to-down underwriting income. Conversely, a print of $11B-plus net income in 2026 with ROE holding above 13% and any capital-return step-up would confirm the current price as a discount to intrinsic value.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has grown from $40.9B (2021) to $59.8B (2025), a ~10% CAGR, with net income expanding from $8.5B to $10.3B and free cash flow running $11-16B annually. Operating cash flow covers net income 1.57x and accruals are negative (-1.9% of assets), both signals of clean, cash-backed earnings - unusually pristine for an insurer where reserve estimation creates latitude. Diluted shares have declined from 442M to 401M (-2.4% CAGR), so per-share economics compound faster than the reported numbers.
Verify before trusting this (5)
- Combined ratio trend and catastrophe-loss experience across 2021-2025
- Reserve development (favorable vs adverse) to confirm underwriting discipline
- Investment portfolio credit quality and duration positioning
- Segment mix - commercial vs personal vs life, and geographic concentration
- Reinsurance recoverables and counterparty exposure
The composite fair value lands at $280.69 and the signal-adjusted FV at $279.29, both implying the stock is about 21% overpriced at $352.54. The anchored PE method independently corroborates around $281, so this isn't a runaway single-method artifact - multiple lenses agree the deserved price sits in the high $270s to low $280s. Earnings quality is good (no haircut needed) and the business is high-quality (Strong, 76), which justifies a premium multiple - but that premium looks already fully embedded in today's price, not still available to the buyer. What's priced in: continuation of the current hard-market pricing environment, mid-teens ROE indefinitely, and no meaningful cat/reserve shock. That's a demanding setup for a cyclical P&C insurer whose hard market will eventually soften. Margin of safety is negative - you're paying up for quality that is already recognized. The right verdict is Rich, not catastrophic: Chubb's earnings durability and buyback cadence limit downside, but the gap is real and the entry price simply isn't attractive.
Verify before trusting this (4)
- Combined ratio trend and any signs of pricing rollover in commercial lines
- Cat load assumptions and reserve development in recent 10-Q
- Investment portfolio yield trajectory as book reprices
- Buyback pace and capital return guidance
Chubb sits in a benign sentiment posture rather than an exciting one. The tape is modestly risk-on with VIX at 15.8 and indices near highs, but with a 0.39 beta this name barely registers macro impulses either way; it is not the vehicle traders reach for in a risk-on rip, nor the one they dump in a wobble. The active narrative is a durable, moderate-intensity steady-compounder story - gold-standard P&C, hard-market pricing power, mid-teens ROE, capital return - which is exactly the kind of low-drama story that keeps a defensive insurer bid without generating meme energy. Cult coefficient is low, so there is no reflexive frenzy to fade or ride. News flow is quiet and constructive: routine leadership appointments and a Zacks-style 'solid growth at a premium - hold or buy?' piece that captures the prevailing analyst tone perfectly. That tone - respectful but valuation-cautious - is the main sentiment friction here: the bear framing of 'paying 26% above DCF for a cyclical' is available to anyone looking for a reason to trim, which caps upside enthusiasm without triggering selling. Net: a mild tailwind from narrative durability and a calm tape, a mild headwind from valuation-anchored analyst caution, and low beta muting both. Balanced, leaning faintly positive.
Verify before trusting this (4)
- Whether the hard-market narrative starts cracking in Q3/Q4 rate commentary from peers (Travelers, AIG) - would strengthen the softening-cycle bear script
- Any major cat event (hurricane season, wildfire) that would flip the tail-risk framing from dormant to active
- Analyst target revisions - are price targets creeping up with the stock or staying anchored, which would widen the 'priced for perfection' overhang
- Sector rotation signals: if risk-on accelerates, defensives like CB may lag on relative sentiment even with positive absolute tape
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 6, 2026, CB was $352.54. We expect it to be $345.50 by Feb 2027, and we consider it great value under $275.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 6, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.